Oxford Biomedica Confirms Aura Biosciences Partnership For Phase 3 Eye Cancer Drug Manufacturing
(RTTNews) - Oxford Biomedica plc (OXB.L), a gene and cell therapy company, on Tuesday confirmed its manufacturing and supply partnership with Aura Biosciences, Inc. (AURA), a biotechnology company.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.